Citadel Advisors’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-400,800
| Closed | -$38.9M | – | 10165 |
|
|
2019
Q3 | $38.9M | Buy |
400,800
+390,300
| +3,717% | +$39.1M | 0.02% | 936 |
|
|
2019
Q2 | $1.07M | Buy |
10,500
+500
| +5% | +$54K | ﹤0.01% | 5584 |
|
|
2019
Q1 | $1.14M | Sell |
10,000
-27,400
| -73% | -$2.01M | ﹤0.01% | 5372 |
|
|
2018
Q4 | $1.46M | Buy |
37,400
+16,600
| +80% | +$720K | ﹤0.01% | 4678 |
|
|
2018
Q3 | $1.14M | Buy |
20,800
+700
| +3% | +$47.9K | ﹤0.01% | 5315 |
|
|
2018
Q2 | $1.66M | Sell |
20,100
-3,600
| -15% | -$278K | ﹤0.01% | 4387 |
|
|
2018
Q1 | $1.58M | Sell |
23,700
-17,000
| -42% | -$982K | ﹤0.01% | 4089 |
|
|
2017
Q4 | $2.09M | Buy |
40,700
+25,700
| +171% | +$1.85M | ﹤0.01% | 3575 |
|
|
2017
Q3 | $1.34M | Buy |
15,000
+11,100
| +285% | +$843K | ﹤0.01% | 3919 |
|
|
2017
Q2 | $233K | Buy |
+3,900
| New | +$218K | ﹤0.01% | 6333 |
|
|
2017
Q1 | – | Sell |
-7,000
| Closed | -$349K | – | 8321 |
|
|
2016
Q4 | $349K | Buy |
7,000
+1,400
| +25% | +$75K | ﹤0.01% | 5457 |
|
|
2016
Q3 | $336K | Sell |
5,600
-2,000
| -26% | -$115K | ﹤0.01% | 5484 |
|
|
2016
Q2 | $389K | Buy |
+7,600
| New | +$325K | ﹤0.01% | 4834 |
|
|
2016
Q1 | – | Sell |
-5,300
| Closed | -$240K | – | 8553 |
|
|
2015
Q4 | $240K | Sell |
5,300
-700
| -12% | -$36.7K | ﹤0.01% | 5548 |
|
|
2015
Q3 | $250K | Sell |
6,000
-1,500
| -20% | -$78.3K | ﹤0.01% | 5831 |
|
|
2015
Q2 | $452K | Buy |
7,500
+3,300
| +79% | +$218K | ﹤0.01% | 5141 |
|
|
2015
Q1 | $326K | Buy |
+4,200
| New | +$242K | ﹤0.01% | 5529 |
|
Citadel Advisors's ONCE Position: Q4 2019 in Review
Citadel Advisors sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 654,852 shares — an estimated $63.5M sold.
Citadel Advisors first reported a position in ONCE in Q1 2015 and held it in 17 quarters. The position peaked at $69.4M in Q1 2019. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.
- Citadel Advisors reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
- Citadel Advisors sold 654,852 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $63.5M.
- Citadel Advisors first reported a position in Spark Therapeutics, Inc. Common Stock in Q1 2015 and held it in 17 quarters.
- Citadel Advisors's Spark Therapeutics, Inc. Common Stock position peaked at $69.4M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.
Based on Citadel Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.